INO PE Ratio & Valuation, Is INO Overvalued

Historical Valuation

Inovio Pharmaceuticals Inc (INO) is now in the Fair zone, suggesting that its current forward PS ratio of 36.67 is considered Fairly compared with the five-year average of -2.74. The fair price of Inovio Pharmaceuticals Inc (INO) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：1.73

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Inovio Pharmaceuticals Inc (INO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Inovio Pharmaceuticals Inc (INO) has a current Price-to-Book (P/B) ratio of -11.73. Compared to its 3-year average P/B ratio of -0.11, the current P/B ratio is approximately 10134.41% higher. Relative to its 5-year average P/B ratio of 0.92, the current P/B ratio is about -1369.49% higher. Inovio Pharmaceuticals Inc (INO) has a Forward Free Cash Flow (FCF) yield of approximately -76.72%. Compared to its 3-year average FCF yield of -102.49%, the current FCF yield is approximately -25.14% lower. Relative to its 5-year average FCF yield of -72.52%, the current FCF yield is about 5.79% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for INO competitors is 12.22, providing a benchmark for relative valuation. Inovio Pharmaceuticals Inc Corp (INO.O) exhibits a P/S ratio of 36.67, which is 199.97% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of INO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of INO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is INO currently overvalued or undervalued?

What is Inovio Pharmaceuticals Inc (INO) fair value?

INO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Inovio Pharmaceuticals Inc (INO) is between to according to relative valuation method.

How does INO's valuation metrics compare to the industry average?

The average P/S ratio for INO's competitors is 12.22, providing a benchmark for relative valuation. Inovio Pharmaceuticals Inc Corp (INO) exhibits a P/S ratio of 36.67, which is 199.97% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Inovio Pharmaceuticals Inc (INO) as of Mar 11 2026?

As of Mar 11 2026, Inovio Pharmaceuticals Inc (INO) has a P/B ratio of -11.73. This indicates that the market values INO at -11.73 times its book value.

What is the current FCF Yield for Inovio Pharmaceuticals Inc (INO) as of Mar 11 2026?

As of Mar 11 2026, Inovio Pharmaceuticals Inc (INO) has a FCF Yield of -76.72%. This means that for every dollar of Inovio Pharmaceuticals Inc's market capitalization, the company generates -76.72 cents in free cash flow.

What is the current Forward P/E ratio for Inovio Pharmaceuticals Inc (INO) as of Mar 11 2026?

As of Mar 11 2026, Inovio Pharmaceuticals Inc (INO) has a Forward P/E ratio of -1.33. This means the market is willing to pay $-1.33 for every dollar of Inovio Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Inovio Pharmaceuticals Inc (INO) as of Mar 11 2026?

As of Mar 11 2026, Inovio Pharmaceuticals Inc (INO) has a Forward P/S ratio of 36.67. This means the market is valuing INO at $36.67 for every dollar of expected revenue over the next 12 months.

INO Valuation